Peter Pattison· @bsc_io_e · X·· 1 天前评分45
正文 · 原文
Presented @ #ESMO26 | #ROWANStudy:
Adverse events were consistent with the known safety profiles of #TheraSphere #Y90 and durvalumab+tremelimumab (STRIDE) #immunotherapy, supporting continued evaluation of TheraSphere in combination with immunotherapy for #livercancer. #HCC
Learn more: https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/presentation/list?q=rowan
7 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Peter Pattison · x.com